The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis.
ATTR
Cardiac amyloidosis
Diagnosis
Mayo score
Scores
Transthyretin
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
revised:
07
08
2024
received:
28
05
2024
accepted:
19
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
aheadofprint
Résumé
Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA. We analysed 362 consecutive patients referred to a third-level centre for suspected CA. Overall, 132 (36%) had transthyretin CA (ATTR-CA), and 91 (25%) immunoglobulin light chain CA (AL-CA); CA was excluded in 139 (38%). ATTR-CM score had a good diagnostic performance to distinguish ATTR-CA from AL-CA or no CA, with an area under the curve (AUC) of 0.795 (95% confidence interval [CI] 0.747-0.842, p < 0.001), and ATTR-CA from no CA (AUC 0.822, 95% CI 0.774-0.871, p < 0.001). Results were consistent in both patients with preserved (AUC 0.787, 95% CI 0.726-0.848, p < 0.001), and reduced or mildly reduced ejection fraction (AUC 0.790, 95% CI 0.709-0.871, p < 0.001). The ATTR-CM score showed a better discrimination compared to IWT and AMYLI score to distinguish ATTR-CA from AL-CA or no CA (p = 0.002), but not to distinguish ATTR-CA from no CA (p = 0.270). Diagnostic accuracy was significantly higher for the ATTR-CM score as compared to the rule-in cut-off of high-sensitivity troponin T. The Mayo ATTR-CM score has a good performance in identifying patients with ATTR-CA, with also better discrimination power when compared to other scores and biomarkers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Garcia‐Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021;23:512–526. https://doi.org/10.1002/ejhf.2140
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 2022;146:1657–1670. https://doi.org/10.1161/CIRCULATIONAHA.122.060852
Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, et al. Treating amyloid transthyretin cardiomyopathy: Lessons learned from clinical trials. Front Cardiovasc Med 2023;10:1154594. https://doi.org/10.3389/fcvm.2023.1154594
Tomasoni D, Aimo A, Merlo M, Nardi M, Adamo M, Bellicini MG, et al. Value of the HFA‐PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. Eur J Heart Fail 2022;24:2374–2386. https://doi.org/10.1002/ejhf.2616
Arana‐Achaga X, Goena‐Vives C, Villanueva‐Benito I, Solla‐Ruiz I, Rengel Jimenez A, Gaspar TI, et al. Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: T‐Amylo. JACC Cardiovasc Imaging 2023;16:1567–1580. https://doi.org/10.1016/j.jcmg.2023.05.002
Boldrini M, Cappelli F, Chacko L, Restrepo‐Cordoba MA, Lopez‐Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:909–920. https://doi.org/10.1016/j.jcmg.2019.10.011
Aimo A, Chubuchny V, Vergaro G, Barison A, Nicol M, Cohen‐Solal A, et al. A simple echocardiographic score to rule out cardiac amyloidosis. Eur J Clin Invest 2021;51:e13449. https://doi.org/10.1111/eci.13449
Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 2022;7:1036–1044. https://doi.org/10.1001/jamacardio.2022.1781
Monda E, Palmiero G, Lioncino M, Rubino M, Caiazza M, Dongiglio F, et al. External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. Int J Cardiol 2021;339:99–101. https://doi.org/10.1016/j.ijcard.2021.07.035
Vergaro G, Castiglione V, Aimo A, Prontera C, Masotti S, Musetti V, et al. N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail 2023;25:335–346. https://doi.org/10.1002/ejhf.2769
Kittleson MM, Maurer MS, Ambardekar AV, Bullock‐Palmer RP, Chang PP, Eisen HJ, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association. Circulation 2020;142:e7–e22. https://doi.org/10.1161/CIR.0000000000000792
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, et al. A year in heart failure: An update of recent findings. ESC Heart Fail 2021;8:4370–4393. https://doi.org/10.1002/ehf2.13760
Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies. Eur J Heart Fail 2022;24:2342–2351. https://doi.org/10.1002/ejhf.2532
Gonzalez‐Lopez E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐Del Moral FJ, Cobo‐Marcos M, Robles C, et al. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–2594. https://doi.org/10.1093/eurheartj/ehv338
Rosenblum H, Masri A, Narotsky DL, Goldsmith J, Hamid N, Hahn RT, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail 2021;23:250–258. https://doi.org/10.1002/ejhf.1974
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009;338:b2393. https://doi.org/10.1136/bmj.b2393